La chaîne d'options affiche les données clés des options sur actions de Moleculin Biotech à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Moleculin Biotech..

Moleculin Biotech (NASDAQ:MBRX) Stock, Chaîne d'Options

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Biotech Inc

Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.59) by 55.93 percent. This is a 21.05 percent decrease over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $4.66 million which beat the analyst consensus estimate of $706.00 thousand by 559.77 percent. This is a 310.40 percent increase over sales of $1.14 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

EDIT

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

<a href="https://www.globenewswire.com/Tracker?data=AgroyJiAoVwZWpbl3I_g5vXwkNryrBhcKWKtKMfwr5SJGrEArF-F94LVj29UByPwOitbzBikvRMaG94-AUB-kjWcMKBb10qs8XHJ_NGO85I=">Beam Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.
"Just weeks after the clearance of our U.S. investigational new drug application, we are pleased to report that the FDA has now granted RMAT designation to BEAM-302, recognizing its potential as a transformative, one-time treatment for patients living with AATD," said Giuseppe Ciaramella, Ph.D., president of Beam Therapeutics. "This designation underscores the strength of our clinical data to date and the promise of base editing to directly correct the genetic mutation that is the root cause of most cases of severe AATD. With RMAT designation enabling closer and more frequent collaboration, we look forward to working with the FDA to accelerate the development of BEAM-302 and bring this potentially curative therapy to AATD patients as safely and swiftly as possible."
The FDA's RMAT designation is designed to support the development and evaluation of regenerative medicines, including genetic therapies, with the intention of addressing serious or life-threatening diseases that have unmet medical needs. RMAT designation provides opportunities for early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval, organizational commitment from senior staff at the agency, opportunities to participate in novel review and development programs, and the potential for a rolling review and priority review of a product's future biologics license application.
Positive initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previously <a href="https://www.globenewswire.com/Tracker?data=DA7vCfMfeWFXeIxzmWuCQbq57-hOQDq3lYcM01eYzAB2DDZYKNsjZwr_iq5_TDmR93QBOR24G6ICtFMNBz4iR0AAgLewn-IQvVD3cuv0TM1xUJyrh4OIAmqse6MMY42kX6v-_EFDrgneDyjxRqX56dJMQ7rYyGNbYI9Q0FsN60LtxsUV4SKfM6WCVgfyqPQg1icVyi4ZHOANTZ4Tk3sS5w6sgMl7aBvX-wWLvbIdaeg=">reported</a> in March, establishing clinical proof of concept as a potential treatment for AATD and in vivo base editing. Preliminary results from the first three single-ascending dose cohorts in Part A of the study demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable, dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the 60 mg dose cohort. Beam has initiated dosing in the fourth cohort of Part A, evaluating 75 mg of BEAM-302, and expects to report updated data at a medical conference in the second half of 2025. Additionally, the company plans to dose the first patient in Part B, which will include AATD patients with mild to moderate liver disease, in the second half of 2025 as well. Beam previously <a href="https://www.globenewswire.com/Tracker?data=qIH9yhF1SSXMfkVvvTYJsHJzgR09c_h4Fzs6J2NhuVvsfsO-MFzw8sKbiBy1aKE9_hIU_LzaNZHs8IDLS6VKRt5dosCJbNgPC64GjaLtiLtUorZWh-uZOh0eY1lQscRRLzzsg_bQAYNSna04P_oxjXcmzQVsk-bNbg9W444LLcc3CfXmp7C9D-vR1A3in00XgQJd-oLO2tZPsad8TI3rigL5twRVo72RY3aPtfB7H0o=">announced</a> the clearance of the U.S. investigational new drug (IND) application for BEAM-302 for the treatment of AATD in March 2025. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
About BEAM-302 BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the PiZ mutation. Patients homozygous for this mutation (PiZZ) represent the majority of patients living with severe AATD disease. A one-time A-to-G correction of the PiZ mutation with Beam's adenine base editor has the potential to simultaneously reduce the aggregation of mutant, misfolded AAT protein that causes toxicity to the liver (Z-AAT), generate therapeutic levels of corrected protein (M-AAT), and increase total and functional AAT in circulation, thereby addressing the underlying pathophysiology of both the liver and lung disease. In addition, the reduction in circulating PiZ aggregates (i.e., polymers) has the potential to further minimize lung inflammation and dysfunction. Importantly, because the native AAT gene would be corrected in its normal genetic location, AAT levels are anticipated to increase physiologically in response to inflammation or infection. This is a critical aspect of AAT's normal function to regulate the body's inflammatory response, which does not occur with currently approved protein replacement therapies. Correction of the PiZ mutation is expected to be durable based on preclinical and clinical evidence.

Biotech

General

BEAM

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Has Been Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency

Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $342.00 thousand which beat the analyst consensus estimate of $144.30 thousand by 137.01 percent. This is a 5.23 percent increase over sales of $325.00 thousand the same period last year.

CATX

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $342.00K Beat $144.30K Estimate

Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $6.38 million which missed the analyst consensus estimate of $6.64 million by 3.89 percent. This is a 28.75 percent increase over sales of $4.96 million the same period last year.

FTEK

Fuel Tech Q1 EPS $(0.02), Inline, Sales $6.38M Miss $6.64M Estimate

WIIM

OPRX

OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sale guidance with its midpoint above estimates.

Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.11 by 12.32 percent. This is a 28.8 percent increase over earnings of $1.84 per share from the same period last year. The company reported quarterly sales of $512.18 million which missed the analyst consensus estimate of $535.04 million by 4.27 percent. This is a 6.19 percent increase over sales of $482.34 million the same period last year.

VTLE

Vital Energy Q1 Adj. EPS $2.37 Beats $2.11 Estimate, Sales $512.18M Miss $535.04M Estimate

Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) sees Q2 sales of $50.000 million-$53.000 million vs $54.73 million analyst estimate.

Guidance

INDI

Indie Semiconductor Sees Q2 Sales $50.000M-$53.000M vs $54.73M Est

indie Semiconductor shares are trading lower after the company reported worse-than-expected Q1 sales results.

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.14) by 7.02 percent. This is a 27.89 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $14.93 million which missed the analyst consensus estimate of $15.95 million by 6.43 percent. This is a 12.48 percent decrease over sales of $17.05 million the same period last year.

ENTA

Enanta Pharma Q2 EPS $(1.06) Beats $(1.14) Estimate, Sales $14.93M Miss $15.95M Estimate

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $54.08 million which missed the analyst consensus estimate of $54.73 million by 1.19 percent. This is a 3.29 percent increase over sales of $52.35 million the same period last year.

Indie Semiconductor Q1 Adj. EPS $(0.08), Inline, Sales $54.08M Miss $54.73M Estimate

Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 21.43 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $12.03 million which missed the analyst consensus estimate of $14.61 million by 17.65 percent. This is a 85.12 percent increase over sales of $6.50 million the same period last year.

CLLS

Cellectis Q1 Adj. EPS $(0.17) Beats $(0.23) Estimate, Sales $12.03M Miss $14.61M Estimate

GigaCloud Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/g45359309/rigetti-computing-reports-first-quarter-2025-financial-results">details of the report.&nbsp;</a>
The Details: Rigetti reported quarterly earnings of 13 cents per share, which beat the analyst consensus estimate of losses of six cents. Quarterly revenue came in at $1.47 million, which missed the analyst consensus estimate of $2.55 million and is down from revenue of $3.05 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
&#8220;Rigetti is proud to be awarded important government-funded projects in the U.S. and U.K. to advance our technology, which demonstrates our continued leadership in superconducting quantum computing,&#8221; says Rigetti CEO Dr. Subodh Kulkarni. 
&#8220;We also are making great strides in developing innovative approaches to scaling to higher qubit count systems, which is possible due to our open and modular system architecture, in-house full-stack expertise, and world-class partners,&#8221; Kulkarni added. 
RGTI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Rigetti stock was down 11.43% at $10.23 after hours Monday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Movers

Tech

RGTI

Rigetti Stock Sinks After Q1 Revenues Miss Estimates: Details

Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) reported quarterly earnings of $1.13 per share. This is a 160.75 percent increase over losses of $(1.86) per share from the same period last year. The company reported $1.07 billion in sales this quarter. This is a 25.78 percent increase over sales of $854.60 million the same period last year.

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Hldgs Q1 EPS $1.13 Up From $(1.86) YoY, Sales $1.07B Up From $854.60M YoY

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.22 million which beat the analyst consensus estimate of $767.50 thousand by 59.22 percent. This is a 76.83 percent decrease over sales of $5.27 million the same period last year.

BOLT

Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

HEPA

Hepion Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq

One would think that being married to a man on his way to changing the world — and raking in billions while doing it — might feel like a front-row seat to something extraordinary. But for Justine Musk, it felt more like disappearing in plain sight.
As Elon climbed the ladder of success, she says she lost track of the person she used to be: a writer, a thinker, a partner — <a href="https://www.benzinga.com/personal-finance/25/03/44570085/elon-musks-first-ex-wife-says-he-kept-pushing-her-to-become-a-blonde-go-platinum-and-when-filed-for-divorce-she-was-numb-but-relieved">not just a blonde fixture</a> in the background of someone else's empire.
And then came the moment that snapped it all into focus: a car crash that didn't kill her, but cracked everything open.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
In her <a href="https://www.marieclaire.com/sex-love/a5380/millionaire-starter-wife/">2010 Marie Claire essay</a>, Justine described it as a "wake-up call." She'd made a wrong turn, gotten hit, and ended up on the side of the road with a wrecked luxury car and a wrecked sense of self. But it wasn't the collision that shook her most.
"I barely recognized myself," she wrote. "I had <a href="https://www.benzinga.com/news/25/03/44402199/elon-musks-first-ex-wife-says-she-sucked-at-being-his-trophy-wife-and-recalls-him-saying-if-you-were-my-employee-i-would-fire-you">turned into a trophy wife — and I sucked at it.</a>"
She wasn't thinking about airbags or broken bones. She was thinking about him.
And in her <a href="https://youtu.be/ptFYmNuRNyQ?si=8IRNZ8Z5q93gHx-M">2014 TED Talk</a>, she put it even more bluntly:
"My first thought was not ‘Thank God I'm alive.' It wasn't ‘Thank God nobody's hurt.' It was, ‘My husband is going to kill me because I wrecked the car.'"
That moment, she said, was more than just a crash.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
She continued, "This was my wake-up call. I had gotten to the point where I was more concerned about my husband's disapproval than the fact that I could have killed myself or somebody else."
She'd been running herself into the ground — agreeing to things she didn't want to do, pushing herself to be thinner, blonder, quieter. She didn't belong to herself anymore. She belonged to the performance. The image. The <a href="https://www.benzinga.com/personal-finance/25/04/44965461/elon-musks-ex-wife-jumped-into-a-random-thread-to-answer-what-it-takes-to-be-a-billionaire-her-message-the-world-doesnt-care-what-you-want">role of supportive wife in a billionaire's world</a>.
On the curb, trembling, with a police officer's water bottle in hand, she knew she couldn't keep going like this. Not for the kids. Not for the marriage. Not for the version of her that once had fire.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Justine says they tried counseling, but just a month and three sessions later, Elon gave her an ultimatum: "Either we fix this marriage today or I will divorce you tomorrow." He filed for divorce the next day.
It wasn't the dramatic ending people might expect. There was no massive blow-up. The damage had been slow, quiet, and cumulative. Like the crash, it built up quietly, until it didn't.
The car crash didn't take her life. But it gave her something else..the first real reason to take it back.
Justine found her voice again by writing, telling her story, and rejecting the idea that success means dimming your light for someone else's spotlight.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'My First Thought Wasn't Thank God I'm Alive' — Elon Musk's Ex-Wife And Mother Of 5 Kids Says She Feared His Reaction More Than A Car Crash Itself

CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 4.17 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $103.89 million which beat the analyst consensus estimate of $103.18 million by 0.68 percent. This is a 0.12 percent decrease over sales of $104.01 million the same period last year.

CMPO

CompoSecure Q1 Adj. EPS $0.25 Beats $0.19 Estimate, Sales $103.89M Beat $103.18M Estimate

Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) affirms FY2025 sales outlook from $200.00 million-$300.00 million to $200.00 million-$300.00 million vs $234.01 million estimate.

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL